- 2020 (33) ▼
- 2019 (41) ▼
- 2018 (21) ▼
- 2017 (10) ▼
- О ЕАГ
- НОВОСТИ И СОБЫТИЯ
- ПОДДЕРЖКА ЕАГ
Statement concerning the impact of SARS-CoV-2 (COVID-19) on the supply of treatment for persons with lysosomal storage disorders (LSDs), including Hunter syndrome (Mucopolysaccharidosis type II or MPS II), type 1 Gaucher disease, Fabry disease and Metachromatic Leukodystrophy (MLD)
At this time, amid the SARS-CoV-2 (COVID-19) outbreak, Takeda continues to foresee no near-term disruption in the supply of Takeda lysosomal storage disorder (LSD) products for the treatment of patients with Hunter syndrome (Mucopolysaccharidosis type II or MPS II), Gaucher disease, Fabry disease and Metachromatic Leukodystrophy (MLD). We are closely monitoring the external environment and are committed to providing updates in a timely manner, as needed.
Takeda’s strategy is to secure product supply continuity for patients through managing adequate levels of inventory and/or alternative suppliers for the production of our medicines. This strategy is generally applied across our global supply chain for key starting materials, excipients, raw materials, APIs, and finished products.
Based on current assessments of our global supply chain, we do not anticipate any potential supply disruption in the near-term due to the SARS-CoV-2 outbreak. Longer-term, it is not yet possible to predict precisely what the impact may be on individual products. We will continue to monitor the situation as it evolves and take all necessary actions in an effort to ensure supply continuity for the people we serve.
Our top priority is to do all we can to make sure our medicines and services continue to reach the patients and physicians who rely on them, while we protect the health of our employees, those who work alongside them, their families and our communities.
For more information on what Takeda is doing in response to the SARS-CoV-2 situation, please visit the Takeda website: https://www.takeda.com/newsroom/featured-topics/coronavirus-efforts/.